Compare 3M Company (MMM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Novartis AG — how do they compare? 3M Company trades at $161.32 (market cap $84.36B), while Novartis AG trades at $143.31 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.2× 3M Company's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Novartis AG for 82 Days on average.
| MMM | NVS | |
|---|---|---|
Market Cap | $84.36B | $268.57B |
Volume | 2,325,301 | 1,532,573 |
Sector | Industrials | Health |
52-Week High | $183.79 | $168.62 |
52-Week Low | $141.10 | $121.80 |
Typical Hold Time | 169 Days | 82 Days |
Enterprise Value | $93.58B | $309.89B |
Dividend Yield | 1.91% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $161.26, down 0.53% with a bearish technical signal despite strong Q2 2026 earnings beats. The company shows robust profitability with 82.77% ROE and 11.9% net margins, though revenue has declined from 2022 peaks. Analyst consensus is mixed with 48% buy ratings and a $191 price target, while recent news highlights operational improvements and litigation management progress.
The outlook balances strong fundamentals against technical weakness and consumer segment challenges. Investment opportunity lies in continued margin expansion and industrial growth, while risks include high debt levels, soft retail demand, and ongoing PFAS litigation costs that could pressure cash flow.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
